The effect of proton pump inhibitors on survival outcomes in advanced hepatocellular carcinoma treated with sorafenib.

CONCLUSION: In a large high-quality dataset, PPI use was not observed to compromise the survival outcomes of advanced HCC patients initiated on sorafenib.
PMID: 32449002 [PubMed - indexed for MEDLINE]

Source: Clinical Genitourinary Cancer - September 18, 2020 Category: Cancer & Oncology Authors: Ruanglertboon W, Sorich MJ, Logan JM, Rowland A, Hopkins AM Tags: J Cancer Res Clin Oncol Source Type: research